Enapotamab vedotin(Seagen Inc.)

Completion of public offering and listing of American Depository Shares (ADSs) on Nasdaq Global Select Market under the symbol “GMAB.” Total gross proceeds from the issuance of new shares amounted to USD 582 million (DKK 3,873 million) with a corresponding increase in share capital of 3,277,500 ordinary shares or 32,775,000 ADSs November 6, 2019; Copenhagen, Denmark; Interim Report for the First Nine Months Ended September 30, 2019 Highlights Completion of public offering and listing of American Depository Shares (ADSs) on Nasdaq Global Select Market under the symbol “GMAB.” Total gross proceeds from the issuance of new shares amounted to USD 582 million (DKK 3,873 million) with a corresponding increase in share capital of 3,277,500 ordinary shares or 32,775,000 ADSs Positive data reported by Novartis for the Phase III ASCLEPIOS I & II studies of subcutaneous ofatumumab in relapsing multiple sclerosis (RMS) DARZALEX ® (daratumumab) approved in the U.S. in combination with bortezomib, thalidomide and dexamethasone (VTd) and in Japan in combination with bortezomib, melphalan and prednisone (VMP) in various multiple myeloma frontline settings Positive topline results for daratumumab in both the Phase III CANDOR and Phase II GRIFFIN studies in various multiple myeloma settings Biologics License Application (BLA) submitted to U.S. Food and Drug Administration (U.S. FDA) for the subcutaneous formulation of daratumumab; standard review received. An extension of marketing authorization for this formulation was also submitted to the European Medicines Agency (EMA) DARZALEX net sales increased 50% compared to the first nine months of 2018 to USD 2,168 million, resulting in royalty income of DKK 2,033 million Genmab is improving its 2019 financial guidance mainly due to positive foreign exchange movements between the USD and DKK resulting in increased milestone income and royalties on sales of DARZALEX “ Genmab made excellent progress across many areas of the business during the third quarter of 2019. Of key significance was the completion of our public offering of American Depositary Shares and listing on the Nasdaq Global Select Market in the U.S. Genmab’s status as a dual listed company both increases our visibility as an innovation powerhouse and provides additional support for the development of our exciting pipeline of antibody product candidates,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab. “Over the past three months advances to this pipeline included positive data readouts for ofatumumab in relapsing multiple sclerosis and daratumumab in multiple myeloma, regulatory submissions for daratumumab and teprotumumab and additional approvals for daratumumab in the U.S. and Asia. In addition, we entered into new strategic collaborations with companies such as Tempus and BliNK Biomedical, which will allow us to expand our pipeline in new directions as Genmab continues to move towards our goal of transforming cancer treatment.” Financial Performance First Nine Months of 2019 Revenue was DKK 2,405 million in the first nine months of 2019 compared to DKK 1,789 million in the first nine months of 2018. The increase of DKK 616 million, or 34%, was mainly driven by higher DARZALEX royalties and reimbursement income from our collaborations with Seattle Genetics and BioNTech, partly offset by the one-time payment from Novartis of USD 50 million (DKK 304 million) during the first nine months of 2018 for lost potential milestones and royalties following announcement of Novartis’ intention to transition Arzerra ® (ofatumumab) to limited availability via compassionate use programs for chronic lymphocytic leukemia (CLL) in non-U.S. markets. Net sales of DARZALEX by Janssen were USD 2,168 million in the first nine months of 2019 compared to USD 1,441 million in the first nine months of 2018, an increase of USD 727 million, or 50%. Operating expenses were DKK 1,943 million in the first nine months of 2019 compared to DKK 1,130 million in the first nine months of 2018. The increase of DKK 813 million, or 72%, was driven by the advancement of tisotumab vedotin and enapotamab vedotin, additional investments in our product pipeline, and the increase in new employees to support the expansion of our product pipeline. Operating income was DKK 462 million in the first nine months of 2019 compared to DKK 659 million in the first nine months of 2018. As anticipated, the decrease of DKK 197 million, or 30%, was driven primarily by increased operating expenses and the one-time payment from Novartis in 2018. Outlook Genmab is improving its 2019 financial guidance published on August 14, 2019 mainly due to positive foreign exchange movements between the USD and DKK resulting in increased milestone income and royalties on sales of DARZALEX. MDKK Revised Guidance Previous Guidance Revenue 5,100 4,800 Operating expenses (2,750) (2,750) Operating income 2,350 2,050 Conference Call Genmab will hold a conference call in English to discuss the results for the first nine months of 2019 today, Wednesday, November 6, at 6:00 pm CET, 5:00 pm GMT or 12:00 pm EST. To join the call dial +1 631 510 7495 (U.S. participants) or +44 2071 928000 (international participants) and provide conference code 7996106. A live and archived webcast of the call and relevant slides will be available at . Contact: Marisol Peron, Corporate Vice President, Communications & Investor Relations T: +1 609 524 0065; E: mmp@genmab.com For Investor Relations: Andrew Carlsen, Senior Director, Investor Relations T: +45 3377 9558; E: acn@genmab.com The interim report contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology that may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on and the risk factors included in Genmab’s final prospectus for our U.S. public offering and listing and other filings with the U.S. Securities and Exchange Commission (SEC), available at does not undertake any obligation to update or revise forward looking statements in the interim report nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law. Genmab A/S and/or its subsidiaries own the following trademarks: Genmab ® ; the Y-shaped Genmab logo ® ; Genmab in combination with the Y-shaped Genmab logo ® ; HuMax ® ; DuoBody ® ; DuoBody in combination with the DuoBody logo ® ; HexaBody ® ; HexaBody in combination with the HexaBody logo ® ; DuoHexaBody ® ; HexElect ® ; and UniBody ® . Arzerra ® is a trademark of Novartis AG or its affiliates. DARZALEX ® is a trademark of Janssen Pharmaceutica NV. Download the full Interim Report for the First Nine Months of 2019 on attachment or at . CVR no. 2102 3884 LEI Code 529900MTJPDPE4MHJ122 Genmab A/S Kalvebod Brygge 43 1560 Copenhagen V Denmark

Genmab A/S, located in Copenhagen, Denmark, raised $506 million with its initial public offering (IPO). The company trades on the Nasdaq under the ticker symbol GMAB. Genmab A/S , located in Copenhagen, Denmark, raised $506 million with its initial public offering (IPO). The company trades on the Nasdaq under the ticker symbol GMAB. The company’s ordinary shares are currently listed on Nasdaq Copenhagen under the GEN symbol. Each American Depository Share (ADS) represents the right to one-tenth of an ordinary share. The Genmab shares are listed on the Nasdaq Copenhagen and the ADSs on the OTC market in the U.S. The company was founded in 1998 and reported $440 million in sales for the 12 months ending March 31, 2019. The company’s portfolio includes two marketed drugs developed with partners. The first is Darzalex (daratumumab), a human CD38 monoclonal antibody approved by the U.S. Food and Drug Administration (FDA) for multiple myeloma. It was developed and marketed with Johnson & Johnson’s Janssen Biotech . The second commercial product is Arzerra (ofatumumab), developed and marketed with Novartis , for specific indications of chronic lymphocytic leukemia. “Our vision is to transform cancer treatment by launching our own proprietary product by 2025 and advancing our pipeline of differentiated and well-tolerated antibodies,” the company stated in the SEC filing. That pipeline includes five product candidates in clinical development and about 20 proprietary and partnered preclinical programs, including two of its internal product candidates. Genmab has either submitted or plans to submit an IND to the FDA or a clinical trial application (CTA) to the European Medicines Agency (EMA) this year for these candidates. The company dosed its first patient in a Phase I/II clinical trial in May 2018 for HexaBody-DR5/DR5 and DuoBody-CD3xCD20 in a Phase I/II trial for B-cell malignancies in July 2018. Genmab also has a proprietary candidate Enapotamab vedotin (HuMax-AXL-ADC) in Phase I/II development for multiple solid tumors including ovarian, cervical, endometrial, thyroid, non-small cell lung cancer, melanoma and sarcoma. It is an antibody-drug conjugate (ADC) that targets Axl and uses technology licensed from Seattle Genetics . An ADC is an antibody for a specific target that is attached by molecular linker to a chemotherapy drug. It allows for more specific delivery of the toxic chemical. Seattle Genetics is also a development partner with Genmab for tisotumab vedotin, currently in Phase II in cervical cancer, ovarian cancer, and solid cancers. It is an ADC targeted to tissue factor (TF), which is involved in tumor signaling and angiogenesis. The company also has partnerships with ADC Therapeutics, BioNTech, Bristol-Myers Squibb, Lundbeck, and Horizon Pharma . Darzalex brought in $90 million in milestone payments, so-called “bio-bucks,” and $262 million in royalties in 2018, which made up almost 76% of Genmab’s revenue last year. It is being evaluated in numerous clinical trials in hopes of expanding its use. However, it is likely to face competition in the near-future from Sanofi and its isatuximab, which is being reviewed by the FDA and the EMA. In 2018, Genmab’s total revenues rose 28% to $455.28 million with 33% net profit growth to $221.55 million. In the first quarter of this year, revenues and net profit dropped 13% and 64%, respectively, hitting $88.95 million and $10.87 million. Genmab’s other marketed product is Arzerra, partnered with Novartis. This drug hasn’t quite caught on, with Novartis reporting net sales of $26 million last year, creating about $5 million in royalties for Genmab. It has been approved for chronic lymphocytic leukemia and is being evaluated for multiple sclerosis.